Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Male and female, ages 18 to 70 years * Diagnosis of plaque psoriasis for 6 months * Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test, must not be pregnant, lactating, breastfeeding or planning pregnancy * Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of the study drug plus 90 days. Exclusion Criteria: * Any significant acute or chronic medical illness * Blood transfusion within 4 weeks of study drug administration * Inability to tolerate oral medication * Positive hepatitis-B (HBV) surface antigen * Positive hepatitis-C (HCV) antibody * Any history or risk for tuberculosis (TB) * Any major illness/condition or evidence of an unstable clinical condition * Chest X-ray findings suspicious of infection at screening * has received ustekinumab, secukinumab or ixekizumab within 6 months of first administration of study medication * Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first administration of study medication * Has received Rituximab within 6 months of first administration of study medication * Topical medications/treatments for psoriasis within 2 weeks of the first administration of any study medication * Any systemic medications/treatments for psoriasis within 4 weeks of the first administration of any study medication Other protocol defined inclusion/exclusion criteria could apply